Prognostic implications of quantitative evaluation of baseline Q-wave width in ST-segment elevation myocardial infarction

Journal of Electrocardiology

Volumn 47, Issue 4, 2014, Pages 465-471

  Bao, Mike H ^a   Zheng, Yinggan ^a   Westerhout, Cynthia M ^a   Fu, Yuling ^a   Wagner, Galen S ^b   Chaitman, Bernard ^c   Granger, Christopher B ^b   Armstrong, Paul W ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c SAINT LOUIS UNIVERSITY   (United States)

Author keywords

Electrocardiogram; Prognosis; Q wave; STEMI; Width

Indexed keywords

PEXELIZUMAB; MONOCLONAL ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ADULT; CARDIOGENIC SHOCK; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; Q WAVE; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; AGED; CLINICAL TRIAL; COMORBIDITY; ELECTROCARDIOGRAPHY; HEART FAILURE; INTERNATIONAL COOPERATION; MIDDLE AGED; MULTICENTER STUDY; MYOCARDIAL INFARCTION; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; COMORBIDITY; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; HEART FAILURE; HUMANS; INTERNATIONALITY; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROGNOSIS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SHOCK, CARDIOGENIC; SINGLE-CHAIN ANTIBODIES; SURVIVAL RATE;

EID: 84905115766     PISSN: 00220736     EISSN: 15328430     Source Type: Journal    
DOI: 10.1016/j.jelectrocard.2014.04.013     Document Type: Conference Paper

References (24)

1. S.G. Goodman, A. Langer, and A.M. Ross et al. Non-Q-wave versus Q-wave myocardial infarction after thrombolytic therapy: angiographic and prognostic insights from the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries-I angiographic substudy. GUSTO-I Angiographic Investigators Circulation 97 5 1998 444 450
2. E. Lockwood, Y. Fu, and B. Wong et al. Does 24-hour ST-segment resolution postfibrinolysis add prognostic value to a Q wave? An ASSENT 2 electrocardiographic substudy Am Heart J 146 4 2003 640 645
3. Y. Birnbaum, A. Chetrit, and S. Sclarovsky et al. Abnormal Q waves on the admission electrocardiogram of patients with first acute myocardial infarction: prognostic implications Clin Cardiol 20 5 1997 477 481
4. P.W. Armstrong, Y. Fu, C.M. Westerhout, and M.P. Hudson et al. Baseline Q-wave surpasses time from symptom onset as a prognostic marker in ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention J Am Coll Cardiol 53 17 2009 1503 1509
5. H. Siha, D. Das, and Y. Fu et al. Baseline Q waves as a prognostic modulator in patients with ST-segment elevation: insights from the PLATO trial CMAJ 184 10 2012 1135 1142
6. C.K. Wong, W. Gao, and O.C. Raffel et al. Initial Q waves accompanying ST-segment elevation at presentation of acute myocardial infarction and 30-day mortality in patients given streptokinase therapy: an analysis from HERO-2 Lancet 367 9528 2006 2061 2067
7. G.S. Wagner, C.J. Freye, and S.T. Palmeri et al. Evaluation of a QRS scoring system for estimating myocardial infarct size. I. Specificity and observer agreement Circulation 65 2 1982 342 347
8. M.G. Jones, K.M. Anderson, and P.W. Wilson et al. Prognostic use of a QRS scoring system after hospital discharge for initial acute myocardial infarction in the Framingham cohort Am J Cardiol 66 5 1990 546 550
9. K. Thygesen, J.S. Alpert, and A.S. Jaffe et al. Third universal definition of myocardial infarction Circulation 126 16 2012 2020 2035
10. P.W. Armstrong, C.B. Granger, and P.X. Adams et al. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial JAMA 297 1 2007 43 51
11. P.W. Armstrong, P.X. Adams, and H.R. Al-Khalidi et al. Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI): a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention Am Heart J 149 3 2005 402 407
12. C.E. Buller, Y. Fu, and K.W. Mahaffey et al. ST-segment recovery and outcome after primary percutaneous coronary intervention for ST-elevation myocardial infarction: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial Circulation 118 13 2008 1335 1346
13. A. Stebbins, R.H. Mehta, and P.W. Armstrong et al. A model for predicting mortality in acute ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: results from the Assessment of Pexelizumab in Acute Myocardial Infarction Trial Circ Cardiovasc Interv 3 5 2010 414 422
14. M.J. Pencina, R.B. D'Agostino Sr., and E.W. Steyerberg Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers Stat Med 30 1 2011 11 21
15. G.B. Myers, H.A. Klein, and T. Hiratzka Correlation of electrocardiographic and pathologic findings in anteroposterior infarction Am Heart J 37 2 1949 205 236
16. G.B. Myers, H.A. Klein, and T. Hiratzka Correlation of electrocardiographic and pathologic findings in posterior infarction Am Heart J 38 4 1949 547 592
17. H. Blackburn, A. Keys, E. Simonson, and P. Rautaharju et al. The electrocardiogram in population studies. A classification system Circulation 21 1960 1160 1175
18. H. White Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial Lancet 358 9296 2001 1855 1863
19. The Asprin Myocardial Infarction Study (AMIS) Trial A randomized, controlled trial of aspirin in persons recovered from myocardial infarction JAMA 243 7 1980 661 669
20. The Thrombolysis in Myocardial Infarction Study Group Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial N Engl J Med 320 10 1989 618 627
21. G.U.S.T.O. The investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction N Engl J Med 329 10 1993 673 682
22. F. Van de Werf, J. Adgey, and D. Ardissino et al. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial Lancet 354 9180 1999 716 722
23. Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Inervention (ASSENT-4 PCI) Investigators. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial Lancet 367 9510 2006 569 578
24. L. Wallentin, R.C. Becker, A. Budaj, C.P. Cannon, H. Emanuelsson, and C. Held et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 11 2009 1045 1057